DaVita HealthCare (DVA) delivered earnings and revenue surprises of +1.06% and +1.34%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Dialysis provider DaVita Inc. (NYSE:DVA) will be reporting earnings this Thursday after the bell. Here’s what investors should know.
More than 35 million U.S. adults have CKD, and most are undiagnosed. This year, DaVita screened nearly 1,000 people across Greater Houston and Los Angeles. It's an authentic neighborhood partnership, "said Liz Gardner, executive director of the DaVita Giving Foundation.
DaVita (DVA) has been pulled back into focus after agreeing to a settlement of up to $15,000,000 related to a ransomware attack in April 2025 that affected patient and financial data. Against this legal backdrop, DaVita’s share price has softened in the short term, with a 1-day share price return of 1.32% lower and a 7-day return of 1.96% lower, while still showing a 60.37% year-to-date share price gain and a 42.15% 1-year total shareholder return. This combination points to earlier momentum...
DaVita (DVA) stock sank 6% on Trump’s Kidney Care National Plan news—see market impact, key metrics, and what to watch ahead of Oct. 29 earnings.
DaVita HealthCare (DVA) closed at $187.25 in the latest trading session, marking a -1.01% move from the prior day.
This is the newest page. Registered accounts read further back.